Open AccessDESIGN, SYNTHESIS, AND DOCKING OF SULFADIAZINE SCHIFF BASE SCAFFOLD FOR THEIR POTENTIAL CLAIM AS INHA ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE INHIBITORS
Author(s) -
Prabha Thangavelu,
T Sivakumar
Publication year - 2018
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2018.v11i10.27179
Subject(s) - inha , antimycobacterial , docking (animal) , in silico , reductase , biochemistry , enzyme , mycobacterium tuberculosis , chemistry , schiff base , biology , combinatorial chemistry , stereochemistry , tuberculosis , medicine , gene , nursing , pathology
Objective: An effort was made to design and synthesize the series of sulfadiazine building blocks as a targeted candidate for antimycobacterial activity.Method: The synthesized compounds were subjected to preliminary in silico screening study for testing their antimycobacterial action by doing their molecular docking study on bioinformatics software, molecular operating environment 2009.10.Result: The results obtained from this tool showed that there is a best docking affinity score of these target compounds against the enzyme InhA Enoyl-(acyl-carrier-protein) reductase from Mycobacterium tuberculosis (MTB) pathogen, which is one of the key enzymes involved in the type II fatty acid biosynthesis pathway of MTB.Conclusion: Thus, the synthesized sulfadiazine Schiff base derivatives might serve as the best drug candidate for the existence of menacing pathogen MTB.